利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.032 秒)

    MULTI-EPITOPE TARP PEPTIDE VACCINE AND USES THEREOF
    2.
    发明申请
    MULTI-EPITOPE TARP PEPTIDE VACCINE AND USES THEREOF 审中-公开
    多环鸟苷类疫苗及其用途

    公开(公告)号：US20160310585A1

    公开(公告)日：2016-10-27

    申请号：US15102996

    申请日：2014-12-12

    申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEP. OF HEALTH AND HUMAN SERVICES

    发明人： Lauren V. Wood ,  Jay A. Berzofsky ,  Brenda D. Roberson ,  Masaki Terabe

    IPC分类号： A61K39/00 ,  A61K9/19

    CPC分类号： A61K39/0011 ,  A61K9/19 ,  A61K2039/5154 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

    摘要： Immunogenic T cell receptor γ alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4+ T cell and CD8+ T cell, as well as humoral, immune responses.

    摘要翻译： 描述了包括TARP蛋白的多个表位的免疫原性T细胞受体γ替代阅读框蛋白（TARP）肽组合物。 所公开的组合物可用于治疗表达TARP的癌症，例如前列腺癌，乳腺癌和间皮瘤。 在一些实施方案中，本文公开的TARP肽组合物包括重叠的TARP肽组，其各自具有约15至约25个氨基酸的长度，并且包含约5至约15个氨基酸，其与至少另外重叠的肽相同 组。 在具体实例中，该组中重叠的TARP肽的组合包括人TARP的完整氨基酸序列。 本文所述的多表位肽组合物包括CD4和CD8表位，对于诱导CD4 + T细胞和CD8 + T细胞以及体液免疫应答是重要的特征。

    LIVE, ATTENUATED RUBELLA VECTOR TO EXPRESS VACCINE ANTIGENS
    4.
    发明申请
    LIVE, ATTENUATED RUBELLA VECTOR TO EXPRESS VACCINE ANTIGENS 有权
    LIVE，衰减的RUBELLA VECTOR TO EXPRESS VACCINE ANTIGENS

    公开(公告)号：US20150079123A1

    公开(公告)日：2015-03-19

    申请号：US14387514

    申请日：2013-04-08

    申请人： The United States of America, as Represented by the Secretary, Dep. of Health and Human Services

    发明人： Ira Berkower ,  Konstantin Virnik

    IPC分类号： A61K39/21 ,  C12N15/86

    CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  C12N15/86 ,  C12N2740/15034 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2770/36221 ,  C12N2770/36234 ,  C12N2770/36243 ,  C12N2770/36271

    摘要： Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) without an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the heterologous antigenic insert is positioned within the rubella structural protein ORF. In some examples, the heterologous antigenic insert is positioned in the rubella structural protein ORF in between a gene encoding structural protein E2 and a gene encoding structural protein E1. Exemplary antigenic inserts include HIV, SIV, RSV or hepatitis B surface antigens. In some examples, the HIV antigenic insert is a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to a particular virus, such as HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors).

    摘要翻译： 本文公开了分离的风疹病毒载体构建体，其包含不含框内缺失的风疹非结构蛋白质开放阅读框（ORF），风疹结构蛋白ORF和异源抗原插入物。 在一个实例中，异源抗原插入物位于风疹结构蛋白ORF内。 在一些实例中，异源抗原插入物位于编码结构蛋白E2的基因和编码结构蛋白E1的基因之间的风疹结构蛋白ORF中。 示例性抗原插入物包括HIV，SIV，RSV或乙型肝炎表面抗原。 在一些实例中，HIV抗原插入物是Gag抗原插入物，gp41抗原插入片段或gp120抗原插入物。 还公开了分离的风疹病毒载体的用途，例如诱导对特定病毒（例如HIV-1）的免疫应答，测试对中和抗体的敏感性，或筛选抗病毒药物（例如蛋白酶抑制剂）。